EAdjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

被引：207

作者：

Kris, Mark G. ^{[2
]}

Gaspar, Laurie E. ^{[5
]}

Chaft, Jamie E. ^{[2
]}

Kennedy, Erin B. ^{[1
]}

Azzoli, Christopher G. ^{[6
]}

Ellis, Peter M. ^{[10
]}

Lin, Steven H. ^{[7
]}

Pass, Harvey I. ^{[3
]}

Seth, Rahul ^{[4
]}

Shepherd, Frances A. ^{[11
]}

Spigel, David R. ^{[9
]}

Strawn, John R. ^{[8
]}

Ung, Yee C. ^{[12
]}

Weyant, Michael ^{[5
]}

机构：

[1] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA

[2] Mem Sloan Kettering Canc Ctr, Hauppauge, NY USA

[3] NYU, Langone Med Ctr, New York, NY USA

[4] Syracuse Univ, Upstate Med Ctr, Syracuse, NY USA

[5] Univ Colorado, Sch Med, Aurora, CO USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] MD Anderson Canc Ctr, Houston, TX USA

[8] Patient Representat, Houston, TX USA

[9] Sarah Cannon Canc Ctr, Nashville, TN USA

[10] Juravinski Canc Ctr, Hamilton Hlth Sci, Hamilton, ON, Canada

[11] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[12] Sunnybrook Reg Canc Ctr, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 25期

关键词：

TYROSINE KINASE INHIBITORS; POSTOPERATIVE RADIOTHERAPY; INTERNATIONAL ASSOCIATION; INDEPENDENT PREDICTOR; PROGNOSTIC MARKER; POOLED ANALYSIS; BAD-NEWS; CHEMOTHERAPY; ADENOCARCINOMA; CLASSIFICATION;

D O I：

10.1200/JCO.2017.72.4401

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell lung cancers. Methods ASCO convened an update panel and conducted a systematic review of the literature, investigating adjuvant therapy in resected non-small-cell lung cancers. Results The updated evidence base covered questions related to adjuvant systemic therapy and included a systematic review conducted by Cancer Care Ontario current to January 2016. A recent American Society for Radiation Oncology guideline and systematic review, previously endorsed by ASCO, was used as the basis for recommendations for adjuvant radiation therapy. An update of these systematic reviews and a search for studies related to radiation therapy found no additional randomized controlled trials. Recommendations Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stage IIA, IIB, or IIIA disease who have undergone complete surgical resections. For individuals with stage IB, adjuvant cisplatin-based chemotherapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a medical oncologist, is recommended to assess benefits and risks of adjuvant chemotherapy for each patient. The guideline provides information on factors other than stage to consider when making a recommendation for adjuvant chemotherapy, including tumor size, histopathologic features, and genetic alterations. Adjuvant chemotherapy is not recommended for patients with stage IA disease. Adjuvant radiation therapy is not recommended for patients with resected stage I or II disease. In patients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a radiation oncologist, is recommended to assess benefits and risks of adjuvant radiation therapy for each patient with N2 disease. (C) 2017 by American Society of Clinical Oncology

引用

页码：2960 / +

页数：17

共 45 条

[21] Three-dimensional conformal radiation therapy for non-small-cell lung cancer: A phase I/II dose escalation clinical trial
Wu, KL
Jiang, GL
Liao, Y
Qian, H
Wang, LJ
Fu, XL
Zhao, S
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (05): : 1336 - 1344
[22] Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer
Zhang, Ting
Yu, Haifeng
Ni, Chao
Zhang, Tao
Liu, Luying
Lv, Qinghua
Zhang, Zhigang
Wang, Zhen
Wu, Dang
Wu, Pin
Chen, Guodi
Wang, Liancong
Wei, Qichun
Huang, Jian
Wang, Xiaojian
SCIENTIFIC REPORTS, 2017, 7
[23] T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer
Wu, Lirong
Zhu, Jun
Rudqvist, Nils-Petter
Welsh, James
Lee, Percy
Liao, Zhongxing
Xu, Ting
Jiang, Ming
Zhu, Xiangzhi
Pan, Xuan
Li, Pansong
Zhou, Zhipeng
He, Xia
Yin, Rong
Feng, Jifeng
FRONTIERS IN IMMUNOLOGY, 2021, 12
[24] Concurrent Chemoradiation Therapy With Docetaxel/Cisplatin Followed by Docetaxel Consolidation Therapy in Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer: Results of a Phase I Study
Huber, Rudolf M.
Borgmeier, Astrid
Flentje, Michael
Willner, Jochen
Schmidt, Michael
Manegold, Christian
Bramlage, Peter
Debus, Juergen
CLINICAL LUNG CANCER, 2010, 11 (01) : 45 - 50
[25] Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy
Guerra, J. L. Lopez
Gomez, D. R.
Lin, S. H.
Levy, L. B.
Zhuang, Y.
Komaki, R.
Jaen, J.
Vaporciyan, A. A.
Swisher, S. G.
Cox, J. D.
Liao, Z.
Rice, D. C.
ANNALS OF ONCOLOGY, 2013, 24 (01) : 67 - 74
[26] Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer
Lee, Hyun Woo
Noh, O. Kyu
Oh, Young-Taek
Choi, Jin-Hyuk
Chun, Mison
Kim, Hwan-Ik
Heo, Jaesung
Ahn, Mi Sun
Park, Seong Yong
Park, Rae Woong
Yoon, Dukyong
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (03): : 621 - 627
[27] Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011
Ko, J. J.
Tudor, R.
Li, H.
Liu, M.
Skolnik, K.
Boland, W. Kells
Macklow, J.
Morris, D.
Bebb, D. G.
CURRENT ONCOLOGY, 2017, 24 (06) : E486 - E493
[28] Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigacio I Divulgacio Oncologica experience
Girones, Regina
Aparisi, Francisco
Garcia-Sanchez, Jose
Sanchez-Hernandez, Alfredo
Garcia Pinon, Francisco
Juan-Vidal, Oscar
EUROPEAN JOURNAL OF CANCER CARE, 2018, 27 (06)
[29] Clinical Predictors of Persistent Mediastinal Nodal Disease After Induction Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer
Kamel, Mohamed K.
Rahouma, Mohamed
Ghaly, Galal
Nasar, Abu
Port, Jeffrey L.
Stiles, Brendon M.
Nguyen, Andrew B.
Altorki, Nasser K.
Lee, Paul C.
ANNALS OF THORACIC SURGERY, 2017, 103 (01) : 281 - 286
[30] Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
Andre, Fabrice
Ismaila, Nofisat
Henry, N. Lynn
Somerfield, Mark R.
Bast, Robert C.
Barlow, William
Collyar, Deborah E.
Hammond, M. Elizabeth
Kuderer, Nicole M.
Liu, Minetta C.
Van Poznak, Catherine
Wolff, Antonio C.
Stearns, Vered
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (22) : 1956 - +

← 1 2 3 4 5 →